<DOC>
	<DOCNO>NCT00006391</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine oxaliplatin topotecan treating patient previously treat ovarian epithelial , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Oxaliplatin Topotecan Treating Patients With Previously Treated Ovarian Epithelial , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxic effect oxaliplatin topotecan patient previously treat ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer . - Determine qualitative quantitative toxic effect regimen patient . - Determine pharmacokinetics regimen patient . - Determine antitumor activity treatment regimen patient . - Determine correlation pharmacokinetic safety data regimen patient . OUTLINE : This dose-escalation , multicenter study . Patients receive oxaliplatin IV 2 hour day 1 15 topotecan IV continuously day 1-15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients measurable disease achieve response may receive additional therapy discretion principal investigator . Cohorts 3-6 patient receive escalate dos oxaliplatin topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Patients follow day 30 . PROJECTED ACCRUAL : A minimum 15 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer Prior chemotherapy require Measurable evaluable disease No symptomatic , untreated brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 4 month Hematopoietic : WBC great 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) OR SGOT great 2.5 time ULN ( 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular : No uncontrolled symptomatic congestive heart failure No unstable angina pectoris No uncontrolled cardiac arrhythmia Other : No active cancer No prior allergy platinum compound No prior allergic reaction appropriate antiemetic ( e.g. , serotonin antagonist ) administer concurrently study No uncontrolled concurrent illness ( e.g. , infection ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No concurrent colony stimulate factor topotecan administration Chemotherapy : See Disease Characteristics No prior highdose chemotherapy require bone marrow peripheral blood stem cell transplantation At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy whole pelvic field At least 2 week since prior radiotherapy recover Surgery : No unresolved sequela result prior surgery Other : At least 4 week since prior investigational drug No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>